WallStSmart

Live Ventures Inc (LIVE)vsPfizer Inc (PFE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Pfizer Inc generates 14059% more annual revenue ($62.58B vs $441.98M). PFE leads profitability with a 12.4% profit margin vs 5.0%. LIVE trades at a lower P/E of 2.7x. PFE earns a higher WallStSmart Score of 49/100 (D+).

LIVE

Hold

44

out of 100

Grade: D

Growth: 4.0Profit: 5.5Value: 8.3Quality: 7.5
Piotroski: 5/9Altman Z: 2.02

PFE

Hold

49

out of 100

Grade: D+

Growth: 2.0Profit: 6.5Value: 4.7Quality: 4.8
Piotroski: 3/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

LIVEUndervalued (+39.6%)

Margin of Safety

+39.6%

Fair Value

$32.30

Current Price

$13.51

$18.79 discount

UndervaluedFair: $32.30Overvalued
PFESignificantly Overvalued (-194.9%)

Margin of Safety

-194.9%

Fair Value

$9.25

Current Price

$27.28

$18.03 premium

UndervaluedFair: $9.25Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LIVE3 strengths · Avg: 9.7/10
P/E RatioValuation
2.7x10/10

Attractively priced relative to earnings

Price/BookValuation
0.4x10/10

Reasonable price relative to book value

Return on EquityProfitability
26.3%9/10

Every $100 of equity generates 26 in profit

PFE4 strengths · Avg: 8.3/10
Market CapQuality
$153.36B9/10

Large-cap with strong market position

Price/BookValuation
1.8x8/10

Reasonable price relative to book value

Operating MarginProfitability
23.9%8/10

Strong operational efficiency at 23.9%

Free Cash FlowQuality
$4.50B8/10

Generating 4.5B in free cash flow

Areas to Watch

LIVE4 concerns · Avg: 3.0/10
Market CapQuality
$39.93M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
5.0%3/10

5.0% margin — thin

Operating MarginProfitability
3.2%3/10

Operating margin of 3.2%

Debt/EquityHealth
1.213/10

Elevated debt levels

PFE4 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
13.772/10

Expensive relative to growth rate

Revenue GrowthGrowth
-1.2%2/10

Revenue declined 1.2%

EPS GrowthGrowth
-21.3%2/10

Earnings declined 21.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : LIVE

The strongest argument for LIVE centers on P/E Ratio, Price/Book, Return on Equity.

Bull Case : PFE

The strongest argument for PFE centers on Market Cap, Price/Book, Operating Margin.

Bear Case : LIVE

The primary concerns for LIVE are Market Cap, Profit Margin, Operating Margin.

Bear Case : PFE

The primary concerns for PFE are Piotroski F-Score, PEG Ratio, Revenue Growth.

Key Dynamics to Monitor

LIVE profiles as a value stock while PFE is a declining play — different risk/reward profiles.

LIVE carries more volatility with a beta of 1.11 — expect wider price swings.

PFE is growing revenue faster at -1.2% — sustainability is the question.

PFE generates stronger free cash flow (4.5B), providing more financial flexibility.

Bottom Line

PFE scores higher overall (49/100 vs 44/100). LIVE offers better value entry with a 39.6% margin of safety. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Live Ventures Inc

CONSUMER CYCLICAL · HOME IMPROVEMENT RETAIL · USA

Live Ventures Incorporated is engaged in flooring manufacturing, steel fabrication and retail businesses in the United States. The company is headquartered in Las Vegas, Nevada.

Visit Website →

Pfizer Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.

Visit Website →

Want to dig deeper into these stocks?